

AMICUS SIGNS HELSINN'S AKYNZEO® ANTI-EMETIC FOR HUNGARY

PRESS RELEASE NO. 20

Amicus SA of Baar, Switzerland and Helsinn Birex Pharmaceuticals Ltd. of Dublin, Ireland signed a Licensing and Distribution agreement under which Amicus will launch and market Akynzeo®, Helsinn's novel combination anti-emetic containing both netupitant and palonosetron, in Hungary.

Baar, Switzerland, January 18th, 2018: Amicus S.A. announced today that it had signed a long-term Licensing and Distribution Agreement with Helsinn Birex Pharmaceuticals Ltd. of Dublin, Ireland. The agreement provides for Amicus to launch Akynzeo®, an oral fixed-dose combination of netupitant (a highly-selective NK1 receptor antagonist) and palonosetron (a clinically and pharmacologically distinct 5-HT3 receptor antagonist) indicated for the prevention of chemotherapy-induced nausea and vomiting (CINV), in Hungary. Amicus has been granted the exclusive right to Akynzeo for sales and marketing in Hungary from Helsinn Healthcare S.A. and will be responsible for continuing access / reimbursement negotiations, and then to promote and scientifically support the launch of Akynzeo in Hungary. Helsinn registered Akynzeo in the EU on June 2nd, 2015.

"I am very pleased to announce this agreement," commented Amicus CEO Jean-Michel Lespinasse. "It marks an important step for our new Amicus organization in Hungary, bringing into our portfolio an important combination therapy in supportive care, and will be synergistic with our existing oncological and hematological presence. It is a privilege to bring Akynzeo to Hungarian patients; this medicine will give those Hungarian patients suffering from chemotherapy-induced nausea and vomiting a safe and efficacious alternative therapy. Helsinn has an exciting pipeline in oncology; it's an honour for Amicus to work with this fine company; we will work hard to make Akynzeo a success in Hungary and shall hope to deepen our cooperation with Helsinn going forward."

About Helsinn

Helsinn is a privately owned cancer care pharmaceutical group with an extensive portfolio of marketed products and a broad development pipeline. Since 1976, Helsinn has been improving the everyday lives of patients, guided by core family values of respect, integrity and quality, through a unique integrated licensing business model working with long standing partners in pharmaceuticals, medical devices and nutritional supplement products. Helsinn is headquartered in Lugano, Switzerland, with operating subsidiaries in Ireland and the US, a representative office in China, as well as a product presence in about 90 countries globally.

For more information, please visit: www.helsinn.com

About Amicus S.A.

Amicus subsidiaries operate in the Balkan and Baltic countries of Croatia, Estonia, Kosovo, Latvia, Lithuania, Macedonia, Montenegro, Serbia and Slovenia. The company commenced operations at its Hungarian affiliate in July 2017 and is currently opening affiliates in Albania and Bulgaria. Set up in 2014, Amicus has gathered outstanding pharmaceutical, Medical Device and OTC / consumer healthcare talent. The company specializes in representing research-based pharmaceutical, medical equipment and self-care brands across the Central and Eastern Europe.

For more info about Amicus, please visit: www.amicuspharma.eu

Contact:

Maja Boskovic, Public Affairs Officer, Amicus

Maja.Boskovic@amicuspharma.eu, Tel: +381 11 4426 321